Biotechnology News

Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris PARIS, France, 1er juillet 2026 – 07h30 CEST – Abivax SA (Euronext Paris : FR0012333284 – ABVX) (« Abivax...

Data support AGAMREE®’s potential use as a treatment across a broad range of chronic inflammatory rare diseases Pratteln, Switzerland, July 1, 2026 – Santhera Pharmaceuticals (SIX: SANN) today notes...

Die Daten untermauern das Potenzial von AGAMREE® als Therapie für ein breites Spektrum chronisch-entzündlicher seltener Erkrankungen Pratteln, Schweiz, 1. Juli 2026 – Santhera Pharmaceuticals (SIX:...

Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical

Abivax Announces Launch of Public Offering of American Depositary Shares PARIS, France – June 30, 2026 – 10:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or...

Abivax annonce le lancement d’une offre au public d’American Depositary Shares PARIS, France – 30 juin 2026 – 22h45 CEST – Abivax SA (Euronext Paris : FR0012333284 – ABVX) (« Abivax » ou la « Société...

DUBLIN, Ireland and BRIDGEWATER, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide,...

DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet...

EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

Mechelen, Belgium; 30 June 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT)...